Despite these difficulties, our experience suggests that in the specific set of GLUT1-DS patients, compliance has proven to be better than in other conditions for which cKD is indicated [18], likely because of the efficacy of the treatment on symptoms. Here, SLC2A1 is linked to chronic kidney disease.